Vertex Pharmaceuticals Incorporated

VRTXNASDAQHealthcare● Active

$443.52

$-3.31(-0.74%)

Market Cap$112.6B

P/E Ratio—

52W High$507.92

52W Low$362.5

Avg Volume1.3M

Open$443.17

Beta0.31

Overview

Vertex Pharmaceuticals Incorporated (VRTX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

VRTX · free cash flow · updated Jun 8, 2026

Core FCF metrics

VRTX · FCF · TTM · margin & CAGR

Free cash flow was $3.19B for FY2025 (fiscal year ending 2025-12-31), up 504.1% year-over-year The FCF margin was 26.4%. Five-year CAGR stands at +1.3%.

FY2025 Free Cash Flow$3.19B▲ +504.1% YoY

Trailing 12M (TTM)$3.71Btrailing 4 quarters sum

FCF Margin26.4%$3.19B ÷ revenue

3-Year CAGR-6.6%FY2022 → FY2025

5-Year CAGR+1.3%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

VRTX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$3.63B(438M)$3.19B▲ +504.1%26.4%

FY2024−$492.6M(298M)−$790.3M▼ 124.1%-7.2%

FY2023$3.54B(258M)$3.28B▼ 16.5%33.2%

FY2022$4.13B(205M)$3.93B▲ +63.0%44.0%

FY2021$2.64B(235M)$2.41B▼ 19.5%31.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

VRTX · P/FCF · FCF yield · FCF per share

Vertex Pharmaceuticals Incorporated (VRTX) trades at a FCF yield of 3.28% and a price-to-free-cash-flow ratio of 30.6x. FCF per share stands at $14.51, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

3.28%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$14.51

TTM FCF ÷ Shares Outstanding

Price / FCF

x30.6

Share Price ÷ FCF per Share

EV / FCF (TTM)

x29.5

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

VRTX · cash flow statement · operating / investing / financing

For FY2025, Vertex Pharmaceuticals Incorporated generated $3.63B in operating cash flow and spent 438M in capital expenditures, yielding $3.19B in free cash flow.

Operating Activities

+$3.63B

Cash from core business operations

2025-12-31

Investing Activities

−$945.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$2.26B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($3.63B) − |CapEx| (438M) = FCF ($3.19B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

VRTX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Vertex Pharmaceuticals IncorporatedYOU

VRTX

$3.19B+504.1%26.5%

16%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Vertex Pharmaceuticals Incorporated (VRTX) reported free cash flow of $3.19B for FY2025 (fiscal year ending 2025-12-31), up 504.1% year-over-year. The FCF margin was 26.4%.

Based on available data, Vertex Pharmaceuticals Incorporated has maintained positive free cash flow for at least 11 fiscal year(s). FCF peaked at $3.93B in FY2022. The 5-year CAGR stands at +1.3%.

Vertex Pharmaceuticals Incorporated's FCF yield is 3.28% and price-to-FCF ratio is 30.6x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

VRTX free cash flow · 8 questions

Vertex Pharmaceuticals Incorporated free cash flow was $3.19B for FY2025, up 504.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $3.71B.

VRTX free cash flowVRTX FCFVRTX FCF 2025VRTX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Vertex Pharmaceuticals Incorporated · Vertex Pharmaceuticals Incorporated SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026